C3361
C3361 is a moderate specific Plasmodium falciparum hexose transporter 1 (PfHT1) and Plasmodium berghei hexose transporter 1 (PbHT1) inhibitor with Ki values of 8.6 and 9.4 μM. C3361 inhibits TgGT1 with a Ki of 82 μM. C3361 attenuates hepatic (IC50 = 15 μM) and ookinete development of P. berghei. C3361 can suppress the growth of blood-stage parasites. C3361 can be used for the research of infection, such as malaria.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 91042-00-1
- 分子式: C17H32O6
- 分子量:332.43
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Parasite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
C3361 reduces 75% ookinete formation[1].
C3361 (1-100 μM, 68 h) prevent the maturation of the liver-stage schizonts in sporozoite-infected hepatoma cells[1].
C3361 shows growth inhibition of P. berghei with an IC50 of 15 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Sporozoite-infected hepatoma cells
-
Concentration:1, 10, 50 and 100 μM
-
Incubation Time:68 h
-
Result:Decreased area of the liver schizonts.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:GFP-expressing parasite-infected blood cells infected mice models[1]
-
Dosage:2 mg/kg
-
Administration:Intraperitoneally injection, daily
-
Result:Reduced 45% parasitemia from days 3-5.
化学情報
-
CAS 番号 91042-00-1
-
分子量 332.43
-
分子式 C17H32O6
-
SMILES
C=CCCCCCCCCCO[C@H]1[C@@H]([C@H](OC([C@@H]1O)O)CO)O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Huang J, et al. Orthosteric-allosteric dual inhibitors of PfHT1 as selective antimalarial agents. Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2017749118. [Content Brief]
[2]. Blume M, et al. A constitutive pan-hexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs. FASEB J. 2011 Apr;25(4):1218-29. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
C3361 関連分類
HY-17656 関連分類
Powered by Bioz